Evercore ISI initiated coverage of Humana (HUM) with an In Line rating and $295 price target The firm has near-term concerns over the potential for mispricing for Medicare Advantage in 2026. Humana’s current valuation fairly balances the company’s risks and opportunities, the analyst tells investors in a research note. Evercore sees Humana’s plan to achieve a top-quartile stars performance as reasonable.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Private Markets: Databricks valued at over $100B in latest fundraising
- UnitedHealth price target raised to $395 from $325 at Morgan Stanley
- Humana price target raised to $330 from $312 at BofA
- Raymond James says pullback in Humana shares creates buying opportunity
- UnitedHealth Stock (UNH) Leads Health Insurer Rally, Humana (HUM) Drops